NRG-GY020
Complete
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Principal Investigator
Status
Complete
Open to Accrual
February 7, 2020
Temporarily Closed to Accrual
February 7, 2020
Open to Accrual
February 18, 2020
Closed to Accrual
August 29, 2022
Closed to Accrual & Treatment
September 5, 2023
Complete
December 30, 2025
Disease Site
Gynecologic [GY] Uterine Corpus
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare the 3-year recurrence-free survival of women with high intermediate risk (HIR) Stage I/II mismatch repair deficient (dMMR) endometrioid endometrial cancer treated with radiation and MK-3475 (pembrolizumab) versus radiation alone.
Patient Population
Women with Stage I or II endometrioid endometrial cancer with documented MMR deficiency.
Target Accrual
168
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
